Relaunch: “Roche Applied Science Industrial Business” Now is “Roche Custom Biotech”

PENZBERG, Germany--(BUSINESS WIRE)-- Effectively July 1, Roche Applied Science (SIX: RO, ROG; OTCQX: RHHBY) Industrial Business was relaunched under the name Roche Custom Biotech. The switch will be accompanied by a complete makeover of the Industrial Business appearance. Besides the new name and slogan – “Expertise you can trust” - there will also be a new web appearance, which is integrated in the Roche Applied Science website. The dedicated objective of the initiative is to increase brand recognition in the life science, pharmaceutical, and diagnostic industry.

“The main goal of the new brand Roche Custom Biotech is to sharpen our profile in the Biotech B2B industry. The brand expresses our outstanding competence and experience in serving our customers in manufacturing.”, said Manfred Baier, Head of Roche Applied Science.

Roche Custom Biotech has been manufacturing and supplying industrial chemistries for thirty years, in particular for use in the diagnostics industry. With a portfolio of over one thousand products, Roche Custom Biotech also custom manufactures to customer needs. Roche is in an outstanding position to fulfill any manufacturing need using state-of-the-art innovative and proprietary technologies. The expanding pharma product portfolio, including Recombinant Trypsin and Liberase Enzyme Blends, are manufactured under GMP regulations, to meet the exacting demands of pharmaceutical manufacturers.

For more information, please visit www.custombiotech.roche.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Liberase is a trademark of Roche.



CONTACT:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]

KEYWORDS:   Europe  Germany  Switzerland

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.